LFG
ALNY icon

Larson Financial Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

Larson Financial Group’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-900
Closed -$369 – 1793
2023
Q3 		$369 Buy
+900
New +$172K ﹤0.01% 1601

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Larson Financial Group's ALNY Position: Q2 2026 in Review

Larson Financial Group increased its Alnylam Pharmaceuticals (ALNY) stake by 89% in Q2 2026, buying an estimated $86.9K and bringing the position to 613 shares worth $185K. The position accounts for ﹤0.01% of the portfolio, ranked #883.

Larson Financial Group first reported a position in ALNY in Q1 2024 and has held it in 10 quarters since. 791 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Larson Financial Group held 613 shares of Alnylam Pharmaceuticals worth $185K as of Q2 2026.
  • Larson Financial Group bought 288 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $86.9K.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Larson Financial Group's portfolio in Q2 2026, its #883 holding.
  • Larson Financial Group first reported a position in Alnylam Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
  • 791 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.